维普中文期刊产品整合服务
14篇 您的检索式:作者名="Kouassi D"
    题名 作者 年代 出处 被引量
1Plasma TAFI antigen variations in healthy subjects显示文摘Chetaille P Alessi MC Kouassi D 2000Thromb Haemost2000,83,6:1
2Plasma TAFI anti-gen variations in healthy subjects显示文摘Chetaille P Alessi M C Kouassi D 2000Thromb Haemost2000,83,6:1
3Plasma TAFI antigen variations in healthy subjects显示文摘 ALESSI MC KOUASSI D 2000J Thromb Haemost2000,83,:1
4Plasma TAFI antigen variations in health subjects显示文摘Chetaille P Alessi M C Kouassi D 2000Thromb Haemost2000,83,6:1
5Plasma TAFI Antigen Variations in Healthy Subjects 显示文摘 Alessi MC Kouassi D 2000Thromb Haemost2000,83,:1
6Effects of the timing of applications on the incompatibility of three fungicides and one isolate of the entomopathogenic fungus Beauveria bassiana (Balsamo) Vuillemin (Deuteromycotina)显示文摘KOUASSI M CODERRE D TODOROVA S I 2003J Appl En tomol2003,127,:1
7Plasma TAFI antigen variations in healthy subjects显示文摘Chetaille P Alessi MC Kouassi D 0,,06:1
8Plasma TAFIantigen variations in healthy subjects显示文摘Chetaille P Alessi MC Kouassi D 2000Thromb Haemost2000,83,:1
9Plasma TAFI antigen variations in healthy suhjects显示文摘Chetaille P Alessi MC Kouassi D 2000Thromh Haemost2000,83,6:1
10Plasma TAFI antigen variations in healthy subjeets显示文摘Chetaille P Alessi MC Kouassi D 2000Thromb Haemost2000,83,7:1
11Plasma TAFI antigen variations in healthy subjects 显示文摘Chetaille P Alessi MC Kouassi D 2000Thromb Haemost2000,83,5:1
12Plasma TAFI antigen variations in healthy subjects显示文摘 ALESSI MC KOUASSI D 2000Thromb Haemost2000,83,:1
13Plasma TAFI antigen variations in health subjects显示文摘 ALESSI MC KOUASSI D et ai 2000Thromb Haemost2000,83,6:1
14Team experience of nasopharyngeal samples reception,decontamination,and sorting during the COVID-19 pandemic(2020)at Institut Pasteur Côte d’Ivoire显示文摘Molecular testing sensitivity,which allows for early diagnosis of the 2019 coronavirus disease(COVID-19),could be affected by sample quality,storage,and transportation timeframe to the laboratory,along with bias related to the pre-analytic phase.The present study reports the selection and decontamination of nasopharyngeal samples during COVID-19 management at the Institut Pasteur Côte d’Ivoire.The objective of this work was to organize sample reception management and report a complete picture of sample selection and decontamination in the context of diagnosis activity decentralization.An administrative note creating the selection and decontamination unit of nasopharyngeal samples initiated activities in May 2020.The required human resources and necessary materials were identified and put in place.Daily activity consisted of receiving,sorting,decontaminating,and sending nasopharyngeal samples to different diagnostic laboratories.Nonconformities were recorded monthly.After a six-month period of activities,from a total amount of 11,401 containers received and decontaminated,174,085 samples were selected.A proportion of 92.0%of these specimens met the diagnostic standards,while 7.0%that were found acceptable showed minor irregularities.Nevertheless,a rate of 1.0%of samples with major abnormalities could not be used for COVID-19 testing and,therefore,were rejected.Additionally,the non-conformity rate was reduced by 2.4%after the first term activity.Sorting and decontamination of nasopharyngeal samples are crucial steps in biosafety optimization for the technical staff and quality improvement of sample care.KouaméInnocent Kolia KipréBertin Guédé Kan Stéphane Kouassi Koby Albert Obro Kpadraux Danielle Odegue Sylvie Mireil Sina-Kouaméle Banga Victor Yepri Mireille Dosso 2021Journal of Biosafety and Biosecurity2021,3,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费